90. Nanoroughened microstructured orthopedic implant surfaces induce osteogenesis via soluble signaling factors produced by MSCs

Berger, Michael B.; Cohen, David J.; Bosh, Kyla B; Gallagher, Michelle B.; Slosar, Paul; Schwartz, Zvi; Boyan, Barbara D.

doi:10.1016/j.spinee.2020.05.193

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, coculture with osteoblasts promotes the osteoblastic differentiation of MSCs. [36][37][38] Notably, the factors and vesicles secreted by osteoblasts differ from those secreted by natural MSCs. 39 For example, the osteogenically differentiated MSCs secrete CXCL9 and bind to VEGF to inhibit endothelial angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Osteogenically differentiated mesenchymal stem cells promote the apoptosis of human umbilical vein endothelial cells in vitro

Chai

Jiang

et al. 2021

Biotech and App Biochem

View full text Add to dashboard Cite

The absence of blood vessels in tissue engineered bone often leads to necrosis of internal cells after implantation, ultimately affecting the process of bone repair. Herein, mesenchymal stem cells (MSCs) and human umbilical vein endothelial cells (HUVECs) were cocultured to induce osteogenesis and angiogenesis. Based on the findings, the number of HUVECs in the coculture system increased in the growth medium group, but decreased in the osteogenic induction medium (OIM) group. Considering that the paracrine effects of MSCs had changed, we tested the genes expression of osteogenically differentiated MSCs. The expression of osteogenic genes in MSCs increased during osteogenesis. Further, the expression levels of pigment epithelial‐derived factor (PEDF) gene and protein, an antivascular factor, were also increased. To verify whether MSCs promote HUVECs apoptosis via PEDF, PEDF was silenced via siRNA. The conditioned medium of differentiated MSCs with PEDF silencing significantly improved the proliferation and apoptosis of HUVECs. Based on further experiments, PEDF mediated the apoptosis and proliferation of HUVECs through p53, BAX/BCL‐2, FAS, and c‐Caspase‐3. However, when PEDF was silenced with siRNA, the osteogenic potential of MSCs was affected. The results of this study provide a theoretical basis for the construction of prevascularized bone tissues in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Under the influence of osteogenic induction, the MSCs secrete a variety of factors to promote their differentiation into osteoblasts. Moreover, coculture with osteoblasts promotes the osteoblastic differentiation of MSCs 36–38 . Notably, the factors and vesicles secreted by osteoblasts differ from those secreted by natural MSCs 39 .…”

Section: Discussionmentioning

confidence: 99%

Osteogenically differentiated mesenchymal stem cells promote the apoptosis of human umbilical vein endothelial cells in vitro

Chai

Jiang

et al. 2021

Biotech and App Biochem

View full text Add to dashboard Cite

show abstract

“…20 Replicating this naturally occurring bone geometry (biomimicry) has been shown to facilitate an osteogenic environment in response to the surface. 21,22 Recently, a Food and Drug Administration (FDA) approved titanium cage with a specific biomimetic surface (Titan nanoLOCK Interbody, Medtronic, Minneapolis, Minnesota, United States) has been introduced. 23 To our knowledge, there are no previous studies reporting the clinical outcome of this new implant in patients undergoing ALIFs.…”

Section: Introductionmentioning

confidence: 99%

Clinical and Radiographic Outcomes of Anterior Lumbar Interbody Fusions Using a Titanium Cage with a Biomimetic Surface

Jowdy,

Soliman,

Quiceno

et al. 2024

J Neurol Surg A Cent Eur Neurosurg

Self Cite

View full text Add to dashboard Cite

OBJECTIVE We analyzed clinical and radiographic outcomes in patients undergoing anterior lumbar interbody fusions (ALIFs) using a new biomimetic titanium fusion cage (Titan nanoLOCK interbody, Medtronic, Minneapolis, Minnesota). This specialized cage employs precise nanotechnology to stimulate inherent biochemical and cellular osteogenic reactions to the implant, aiming to amplify the rate of fusion. To our knowledge, this is the only study to assess early clinical and radiographic results in ALIFs. METHODS We conducted a retrospective review of data for patients who underwent single or multilevel ALIF using this implant between October 2016 and April 2021. Indications for treatment were spondylolisthesis, post-laminectomy syndrome, or spinal deformity. Clinical and radiographic outcome data for these patients were collected and assessed. RESULTS A total of 84 patients were included. The mean clinical follow-up was 36.6±14 months. At 6 months, solid fusion was seen in 97.6% of patients. At 12 months, solid fusion was seen in 98.8% of patients. Significant improvements were seen in patient-reported outcome measures (PROMs) (visual analog scale and Oswestry Disability Index) at 6 and 12 months compared to the preoperative scores (P<0.001). One patient required reoperation for broken pedicle screws 2 days after the ALIF. None of the patients required readmission within 90 days of surgery. No patients experienced an infection. CONCLUSIONS ALIF using a new titanium interbody fusion implant with a biomimetic surface technology demonstrated high fusion rates (97.6%) as early as 6 months. There was significant improvement in PROMs at 6 and 12 months

show abstract

90. Nanoroughened microstructured orthopedic implant surfaces induce osteogenesis via soluble signaling factors produced by MSCs

Cited by 2 publications

References 0 publications

Osteogenically differentiated mesenchymal stem cells promote the apoptosis of human umbilical vein endothelial cells in vitro

Osteogenically differentiated mesenchymal stem cells promote the apoptosis of human umbilical vein endothelial cells in vitro

Clinical and Radiographic Outcomes of Anterior Lumbar Interbody Fusions Using a Titanium Cage with a Biomimetic Surface

Contact Info

Product

Resources

About